Study summary
A pill that replaces the missing brain signal nearly restored normal wakefulness
+19.8 minmore time staying awake on a standard sleepiness test
What was tested
Oveporexton, a pill that activates orexin receptors (the signal missing in narcolepsy type 1), against placebo, in two phase 3 trials.
What they found
- Ability to stay awake on a standardized test improved by up to 19.8 minutes, vs under 1 minute with placebo.
- Daytime sleepiness scores dropped about 10 points more than with placebo.
- Weekly cataplexy attacks fell 79% to 89%, vs 28% to 39% with placebo.
- Side effects, mostly urinary, were common: 86-89% vs 43-54% with placebo.
What it means
The first drug to target the actual cause of narcolepsy type 1 (a loss of orexin-producing brain cells), not just mask the symptoms. Brand name Orzeyful.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.